Ventoxen 100mg tablet is an anticancer drug used to treat (white blood cell malignancy. Ventoxen, also known as Venetoclaxcccc, is an FDA-approved drug used to treat adults with chronic lymphocytic leukemia. Ventoxen together with Rituximab is used to treat adult patients with chronic lymphocytic leukemia (CLL) who have had at least one previous treatment. Venetoxen is available in the form of an orally administered tablet. It is typically taken with a meal and water once per day. Venetoxen is taken at approximately the same time every day.Venetoclax 100 mg tablet is an anticancer drug used to treat white blood cell malignancy.

Introduction:

Ventoxen 100 mg  is an anticancer drug used to treat white blood cell cancers. Ventoxen Tablet is indicated to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.Venetoclax, commonly known as Venclexta, is an FDA-approved drug that treats adults with chronic lymphocytic leukemia. Ventoxen and Rituximab are used to treat adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior treatment. Venetoxen is available as an oral tablet.

Drug/Therapeutic Class:

Cytotoxic Chemotherapy.

Therapeutic Indication:

Ventoxen monotherapy is recommended for treating chronic lymphocytic leukemia (CLL)  in adult patients with a 17p deletion or TP53 mutation who are unsuitable for or have failed a B-cell receptor pathway inhibitor. Ventoxen 100 mg is also used in adult patients who have failed both chemo immunotherapy and a B-cell receptor pathway inhibitor. Ventoxen is used together with Rituximab is indicated for treating adult patients with chronic lymphocytic leukemia.

Ventoxen 100 mg Pharmacology:

Ventoxen 100 mg (Venetoclax) is a small-molecule inhibitor of the antiapoptotic protein BCL-2 that is both selective and orally accessible. Overexpression of BCL-2 has been shown in chronic lymphocytic leukemia CLL cells, where it promotes tumor cell survival and is related with chemotherapy resistance. Ventoxen 100 mg (Venetoclax) restores the apoptosis process by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins such as BIM, causing mitochondrial outer membrane permeabilization, and activating caspases. In nonclinical research, Venetoclax 100 mg has been shown to be cytotoxic in tumor cells overexpressing BCL-2.

Dosage and Administration:

The beginning dose is 20 milligrams of Ventoxen 100 mg (Venetoclax)  once a day for seven days. The dose must be gradually increased over a 5-week period until it reaches 400 mg per day. The 5-week dose-titration regimen is intended to gradually reduce tumor burden (debulk) while lowering the risk of tumor lysis syndrome.The post-titration dose for Ventoxen 100 mg (Venetoclax)  when used with Rituximab is 400 mg once day. Rituximab should be given after the patient has finished the dose-titration regimen and taken the recommended daily dose of 400 mg Ventoxen 100 mg (Venetoclax)  for 7 days. Ventoxen 100 mg (Venetoclax)  should be used for 24 months starting with Cycle 1 Day 1 of Rituximab. Post-titration dose of Ventoxen 100 mg  monotherapy: The usual dosage of Ventoxen 100 mg (Venetoclax)  is 400 mg once daily. Treatment should be continued until the disease progresses or the patient no longer tolerates it.

Drug Interaction:

Co-administration of 400 mg once daily ketoconazole, a potent inhibitor of CYP3A, P-gp, and BCRP, for 7 days in 11 previously treated NHL patients increased Ventoxen Cmax by 2.3-fold and AUC by 6.4-fold. Co administration of 50 mg once daily ritonavir, a potent CYP3A and P-gp inhibitor, for 14 days in six healthy subjects enhanced Ventoxen Cmax by 2.4-fold and AUC by 7.9-fold. Co-administration of Ventoxen with other powerful CYP3A inhibitors is expected to enhance Ventoxen AUC by 5.8 to 7.8 times. Concomitant use of Ventoxen with strong CYP3A inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, ritonavir) at beginning and during dose titration is not recommended due to an increased risk of TLS. Patients who have finished the dosage-titration period and are on a consistent daily dose of Ventoxen should reduce their Ventoxen dose by 50% when taking moderate CYP3A inhibitors and 75% while taking strong CYP3A inhibitors. Patients should be continuously monitored for signs of toxicity, and the dose may need to be modified. The Ventoxen dose used previous to starting the CYP3A inhibitor should be resumed two to three days after stopping the inhibitor. Grapefruit products, Seville oranges, and starfruit (carambola) should be avoided while taking Ventoxen since they contain CYP3A inhibitors.

OVERDOSE:

There is no specific antidote to Ventoxen 100 mg (Venetoclax) . Patients who overdose should be closely watched and receive appropriate supportive treatment. During the dose-titration phase, patients should be closely monitored for TLS symptoms (fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, muscle or joint pain, abdominal pain, and distension), as well as other toxicities.

Pregnancy & Lactation:
There is no human data on its use in pregnant women. Based on its mechanism of action and observations in animals, it may cause embryofetal damage when taken to a pregnant woman. Females with reproductive potential should receive pregnancy testing before beginning. Advise females with reproductive potential to take effective contraception during therapy and for at least 30 days following the final dosage. Treatment may affect male fertility. Breastfeeding mothers should quit breastfeeding while treatment and for at least one week after the final dosage due to unknown distribution in human breast milk.

Storage Conditions:

Ventoxen 100 mg should be kept between 25°C and 30°C at room temperature. When a medication is no longer needed or has expired, dispose of it safely. Protect from sunlight and humidity. Keep Ventoxen 100 mg and all medicines out of the reach of children.

See more Oncology medicine visit our Shop